Cerebral palsy differential diagnosis: Difference between revisions
Iqra Qamar (talk | contribs) |
Iqra Qamar (talk | contribs) |
||
Line 192: | Line 192: | ||
* MRI : frontal and temporal atrophy | * MRI : frontal and temporal atrophy | ||
|- | |- | ||
|Ataxia-telangiectasia | |||
|<nowiki>-</nowiki> | |||
|<nowiki>-</nowiki> | |||
|<nowiki>+</nowiki> | |||
|<nowiki>-</nowiki> | |||
| | | | ||
* Progressive cerebellar ataxia | |||
* Abnormal eye movements | |||
* Oculocutaneous telangiectasias | |||
* Immune deficiency | |||
* Increased risk of malignancy | |||
| | | | ||
* Elevated serum alpha-fetoprotein level | |||
* Low IgA and IgG levels | |||
* Lymphopenia | |||
* Genetic testing for mutation in the ATM gene | |||
| | | | ||
|- | |||
|Pontocerebellar hypoplasias | |||
| - | |||
| + | |||
| - | |||
| - | |||
| | | | ||
* Progressive muscle atrophy | |||
* Microcephaly | |||
* Developmental delay | |||
|Genetic testing for PCH gene mutations | |||
| | | | ||
* MRI : small cerebellum and brainstem including the pons | |||
|- | |||
|Metachromatic leukodystrophy | |||
| - | |||
| + | |||
| + | |||
| - | |||
| | | | ||
* Regression of motor skills | |||
* Seizures | |||
* Optic atrophy | |||
* Reduced or absent deep tendon reflexes | |||
* Intellectual disability | |||
| | | | ||
* Deficient arylsulfatase A enzyme activity in leukocytes or cultured skin fibroblasts | |||
| | |||
|- | |||
|Pelizaeus-Merzbacher | |||
| + | |||
| - | |||
| + | |||
| - | |||
| | |||
* Nystagmus | |||
* Cognitive impairment | |||
* Onset in infancy | |||
* Slowly progressive | |||
* Language development may be normal | |||
| | |||
* Genetic testing for mutations in PLP1 gene | |||
|MRI shows white matter abnormalities | |||
|- | |||
|Angelman syndrome | |||
| - | |||
| - | |||
| + | |||
| - | |||
| | |||
* Profound intellectual disability | |||
* Postnatal microcephaly | |||
* Typical abnormal behaviors (paroxysmal laughter, easily excitable) | |||
| | |||
* Methylation studies and chromosome microarray to detect chromosome 15 anomalies and UBE3A mutations | |||
| | |||
|- | |||
|Rett syndrome | |||
| + | |||
| - | |||
| - | |||
| + | |||
| | |||
* Occurs almost exclusively in females | |||
* Normal development during first six months followed by regression and loss of milestones | |||
* Loss of speech capability | |||
* Stereotypic hand movements | |||
* Seizures | |||
* Autistic features | |||
| | |||
* Clinical diagnosis | |||
* Genetic testing for MECP2 mutations | |||
| | |||
|- | |||
|Lesch-Nyhan syndrome | |||
| + | |||
| - | |||
| - | |||
| + | |||
| | |||
* Self-mutilating behavior | |||
* Urinary stones due to hyperuricemia | |||
| | |||
* Elevated uric acid level | |||
* Abnormal enzymatic activity of HPRT in cultured fibroblasts | |||
* Genetic testing for HPRT gene mutations | |||
| | | | ||
|} | |} |
Revision as of 19:56, 3 October 2017
Cerebral palsy Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cerebral palsy differential diagnosis On the Web |
American Roentgen Ray Society Images of Cerebral palsy differential diagnosis |
Risk calculators and risk factors for Cerebral palsy differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
Differentiating Cerebral Palsy from other Diseases
- Cerebral Palsy must be differentiated from other slowly progressive diseases such as neurodegenerative disease or metabolic disorders.
- Presence of any of the following factors may suggest an alternative diagnosis:[1]
- Family history of any CNS disease
- Progressive worsening of neurological symptoms
- Symptoms worsened during stress such as illness or fasting
- Absence of any specific risk factor causing cerebral palsy
- Hypotonia with weakness
- Failure to develop milestones normally
- Clinical findings such as muscle atrophy, ataxia, sensory disturbances and involuntary movements
- Cerebral Palsy must be differentiated from
- Inherited Metabolic Disorders Overview
- Intellectual Disability
- Metabolic Myopathies
- Metabolic Neuropathy
- Traumatic Peripheral Nerve Lesions
- Tumors of the Conus and Cauda Equina
- Vascular Malformations of the Spinal Cord
- As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Preferred Table
Diseases | Type of motor abnormality | Clinical findings | Laboratory findings and diagnostic tests | Radiographic findings | |||
---|---|---|---|---|---|---|---|
Spasticity | Hypotonia | Ataxia | Dystonia | ||||
Leigh syndrome | - | - | + | + |
|
|
|
Niemann-Pick disease type C | - | - | + | + |
|
|
|
Infantile Refsum disease | - | + | + | - |
|
Elevated plasma VLCFA levels | |
Adrenoleukodystrophy | + | - | - | - |
|
|
|
Zellweger syndrome | - | + | - | - |
|
|
|
Pyruvate dehydrogenase deficiency | + | + | + | - |
|
|
|
Arginase deficiency | + | - | - | - |
|
|
|
Holocarboxylase synthetase deficiency | - | + | - | - |
|
Elevated levels of:
|
|
Glutaric aciduria type 1 | - | - | - | + |
|
Elevated levels of:
|
|
Ataxia-telangiectasia | - | - | + | - |
|
|
|
Pontocerebellar hypoplasias | - | + | - | - |
|
Genetic testing for PCH gene mutations |
|
Metachromatic leukodystrophy | - | + | + | - |
|
|
|
Pelizaeus-Merzbacher | + | - | + | - |
|
|
MRI shows white matter abnormalities |
Angelman syndrome | - | - | + | - |
|
|
|
Rett syndrome | + | - | - | + |
|
|
|
Lesch-Nyhan syndrome | + | - | - | + |
|
|